Oil prices hold sharp losses with focus on secondary India tariffs
SAN DIEGO, CA - Halozyme Therapeutics , Inc. (NASDAQ:HALO), a biopharmaceutical company with a market capitalization of $7.4 billion, announced today that board member Connie L. Matsui has decided not to seek reelection at the upcoming 2025 annual meeting of stockholders. Matsui, who has been part of the Halozyme board for nearly 18 years, informed the company of her decision on Monday. The company has demonstrated strong performance, achieving a 68% return over the past year according to InvestingPro data.
The company expressed its gratitude to Matsui for her long service and valuable contributions. Halozyme emphasized that her departure is not due to any disagreements regarding the company's operations, policies, practices, or strategy, nor with the company's management or the Board of Directors.
Halozyme Therapeutics specializes in the development of oncology therapies and is known for its proprietary enzyme technology used in drug delivery. The company's statement clarified that Matsui's decision to leave the board was a personal one and unrelated to any internal disputes or issues with the company's direction.
The news of Matsui's upcoming departure comes as Halozyme continues to navigate the competitive landscape of the biotech industry, focusing on creating innovative treatments for cancer patients.
As Halozyme prepares for its 2025 annual meeting, the process for electing a new director to replace Matsui will commence, with further details to be shared in due course. The company's leadership and the remaining board members will continue to guide Halozyme's strategic decisions and oversee the company's growth.
This announcement is based on a press release statement provided in a recent SEC filing by Halozyme Therapeutics, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.